List of therapeutic monoclonal antibodies

Short description: none

Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

* mab: whole monoclonal antibody
* Fab: fragment, antigen-binding (one arm)
* F(ab')2: fragment, antigen-binding, including hinge region (both arms)
* Fab': fragment, antigen-binding, including hinge region (one arm)
* Variable fragments:
* scFv: single-chain variable fragment
* di-scFv: dimeric single-chain variable fragment
* sdAb: single-domain antibody
* BsAb: bispecific monoclonal antibody:
* 3funct: trifunctional antibody
* BiTE: bi-specific T-cell engager

This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by expanding it with reliably sourced entries.

Name | Brand name | Type | Source | Target | Approved | Use

|
|
|
|
|
|

3F8 |  | mab | mouse | GD2 ganglioside |  | neuroblastoma
Abagovomab[1] |  | mab | mouse | CA-125 (imitation) |  | ovarian cancer
Abciximab[2] | ReoPro | Fab | chimeric | CD41 (integrin alpha-IIb) | Y[3] | platelet aggregation inhibitor
Abituzumab[4] |  | mab | humanized | CD51 |  | cancer
Abrezekimab[5] |  | Fab | humanized | IL-13 |  |
Abrilumab[6] |  | mab | human | integrin α4 β7 |  | inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab[6] |  | mab | human | Clostridium difficile |  | Clostridium difficile colitis
Adalimumab[7] | Humira | mab | human | TNF-α | Y[8] | rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hemolytic disease of the newborn
Adecatumumab[9] |  | mab | human | EpCAM |  | prostate and breast cancer
Aducanumab[10] | Aduhelm | mab | human | Amyloid beta | Y[11] | Alzheimer's disease
Afasevikumab[12] |  | mab | human | IL-17A, IL-17F |  | multiple sclerosis
Afelimomab[2] |  | F(ab')2 | mouse | TNF-α |  | sepsis
Alacizumab pegol[13] |  | F(ab')2 | humanized | VEGFR2 |  | cancer
Alemtuzumab[14] | Lemtrada, Campath | mab | humanized | CD52 | Y | multiple sclerosis
Alirocumab[15] | Praluent | mab | human | PCSK9 | Y | hypercholesterolemia
Altumomab pentetate | Hybri-ceaker | mab | mouse | Carcinoembryonic antigen (CEA) |  | colorectal cancer (diagnosis)
Amatuximab[16] |  | mab | chimeric | mesothelin |  | cancer
Amivantamab | Rybrevant | BsAb | human | Epidermal growth factor receptor (EGFR), cMet | Y | non-small cell lung cancer
Anatumomab mafenatox[17] |  | Fab | mouse | Tumor-associated glycoprotein 72 (TAG-72) |  | non-small cell lung cancer
Andecaliximab[18] |  | mab | chimeric | gelatinase B |  | gastric cancer or gastroesophageal junction adenocarcinoma
Anetumab ravtansine[4] |  | mab | human | mesothelin (MSLN) |  | cancer
Anifrolumab[4] | Saphnelo | mab | human | IFN-α/β receptor | Y[19] | systemic lupus erythematosus
Ansuvimab | Ebanga | mab | human | Ebola virus glycoprotein | Y | treatment of Zaire ebolavirus (Ebola virus)
Anrukinzumab[13]
(= IMA-638)[20] |  | mab | humanized | IL-13 |  | asthma
Apolizumab[21] |  | mab | humanized | HLA-DR |  | hematological cancers
Aprutumab ixadotin[22] |  | mab | human | FGFR2 |  |
Arcitumomab[23] | CEA-Scan | Fab' | mouse | Carcinoembryonic antigen (CEA) |  | gastrointestinal cancers (diagnosis)
Ascrinvacumab[12] |  | mab | human | activin receptor-like kinase 1 |  | cancer
Aselizumab[24] |  | mab | humanized | L-selectin (CD62L) |  | severely injured patients
Atezolizumab[25] | Tecentriq | mab | humanized | PD-L1 | Y | cancer
Atidortoxumab[26] |  | mab | human | Staphylococcus aureus alpha toxin |  |
Atinumab[16] |  | mab | human | RTN4 |  |
Atoltivimab |  | mab | human |  |  | part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Atoltivimab/maftivimab/odesivimab | Inmazeb | mab | human |  | Y | treatment of Zaire ebolavirus (Ebola virus)
Atorolimumab[2] |  | mab | human | Rhesus factor |  | hemolytic disease of the newborn[citation needed]
Avelumab[12] | Bavencio | mab | human | PD-L1 | Y | cancer
Azintuxizumab vedotin[27] |  | mab | chimeric/
humanized | CD319 |  | cancer
Bamlanivimab[28] |  | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Emergency Use Authorization (EUA) when used with etesevimab[29] | COVID-19
Bapineuzumab[30] |  | mab | humanized | β-amyloid |  | Alzheimer's disease
Basiliximab[31] | Simulect | mab | chimeric | CD25 (α chain of IL-2 receptor) | Y | prevention of organ transplant rejections
Bavituximab[1] |  | mab | chimeric | phosphatidylserine |  | cancer, viral infections
BCD-100 |  |  | human | PD-1 |  | melanoma
Bebtelovimab[32] |  | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Emergency Use Authorization (EUA)[33] | COVID-19
Bectumomab[31] | LymphoScan | Fab' | mouse | CD22 |  | non-Hodgkin's lymphoma (detection)
Bedinvetmab[34] | Librela[35] | mab | veterinary | nerve growth factor (NGF)[35] | Y | pain associated with osteoarthritis in dogs[35]
Begelomab[6] |  | mab | mouse | DPP4 |  |
Belantamab mafodotin[5] | Blenrep | mab | humanized | B-cell maturation antigen (BCMA) | Y | relapsed or refractory multiple myeloma
Belimumab[36] | Benlysta | mab | human | B-cell activating factor (BAFF) | Y | systemic lupus erythematosus without renal or CNS involvement
Bemarituzumab[26] |  | mab | humanized | FGFR2 |  | gastric cancer or gastroesophageal junction adenocarcinoma
Benralizumab[37] | Fasenra | mab | humanized | CD125 | Y | asthma
Berlimatoxumab[26] |  | mab | human | Staphylococcus aureus bi-component leukocidin |  |
Bermekimab[31] | Xilonix | mab | human | IL-1α |  | colorectal cancer
Bersanlimab[5] |  | mab | human | ICAM-1 |  |
Bertilimumab[24] |  | mab | human | CCL11 (eotaxin-1) |  | severe allergic disorders
Besilesomab[38] | Scintimun | mab | mouse | Carcinoembryonic antigen (CEA)-related antigen |  | inflammatory lesions and metastases (detection)
Bevacizumab[14] | Avastin | mab | humanized | VEGF-A | Y | metastatic cancer, retinopathy of prematurity
Bezlotoxumab[31] | Zinplava | mab | human | Clostridium difficile | Y | Clostridium difficile colitis
Biciromab[31] | FibriScint | Fab' | mouse | fibrin II, beta chain |  | thromboembolism (diagnosis)
Bimagrumab[39] |  | mab | human | ACVR2B |  | myostatin inhibitor
Bimekizumab[10] | Bimzelx | mab | humanized | IL-17A, IL-17F, IL-17AF | Y | psoriasis
Birtamimab |  | mab | chimeric | serum amyloid A protein |  | amyloidosis
Bivatuzumab[31] |  | mab | humanized | CD44 v6 |  | squamous cell carcinoma
Bleselumab[12] |  | mab | human | CD40 |  | organ transplant rejection
Blinatumomab[31] | Blincyto | BiTE | mouse | CD19 | Y | pre-B Acute lymphoblastic leukemia (ALL) (CD19+)
Blontuvetmab[40] | Blontress | mab | veterinary | CD20 |  |
Blosozumab[41] |  | mab | humanized | SOST |  | osteoporosis
Bococizumab[31] |  | mab | humanized | PCSK9 |  | dyslipidemia
Brazikumab[18] |  | mab | human | IL-23 |  | Crohn's disease
Brentuximab vedotin[31] | Adcentris | mab | chimeric | CD30 (TNFRSF8) | Y | Hodgkin's lymphoma, anaplastic large-cell lymphoma
Briakinumab[31] |  | mab | human | IL-12, IL-23 |  | psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab[41] | Siliq | mab | human | IL-17 | Y | Plaque psoriasis
Brolucizumab[25] | Beovu | scFv | humanized | vascular endothelial growth factor A (VEGFA) | Y | wet age-related macular degeneration
Brontictuzumab[6] |  | mab | humanized | Notch 1 |  | cancer
Burosumab[18] | Crysvita | mab | human | FGF 23 | Y | X-linked hypophosphatemia
Cabiralizumab[40] |  | mab | humanized | CSF1R |  | metastatic pancreatic cancer
Camidanlumab tesirine[26] |  | mab | human | CD25 (α chain of IL-2 receptor) |  | B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia
Camrelizumab[22] |  | mab | humanized | PD-1 |  | hepatocellular carcinoma
Canakinumab[42] | Ilaris | mab | human | IL-1 | Y | cryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease
Cantuzumab mertansine[41] |  | mab | humanized | CanAg (a glycoform of MUC1) |  | colorectal cancer etc.
Cantuzumab ravtansine[41] |  | mab | humanized | CanAg (a glycoform of MUC1) |  | cancers
Caplacizumab[43] | Cablivi | sdAb | humanized | VWF | Y | thrombotic thrombocytopenic purpura, thrombosis
Casirivimab[28] |  | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Yes when used with imdevimab[44][45] | COVID-19
Capromab[31] | Prostascint | mab | mouse | Glutamate carboxypeptidase II | Y | prostate cancer (detection)
Carlumab[16] |  | mab | human | MCP-1 |  | oncology/immune indications
Carotuximab[40] |  | mab | chimeric | endoglin |  | angiosarcoma
Catumaxomab[30] | Removab | 3funct | rat/mouse hybrid | EpCAM, CD3 | Y | ovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugate |  | mab | humanized | Lewis-Y antigen |  | cancer
Cedelizumab[46] |  | mab | humanized | CD4 |  | prevention of organ transplant rejections, treatment of autoimmune diseases
Cemiplimab[31] | Libtayo | mab | human | PD-1 | Y | cutaneous squamous cell carcinoma
Cergutuzumab amunaleukin[12] |  | mab | humanized | IL-2 |  | cancer
Certolizumab pegol[42] | Cimzia | Fab' | humanized | TNF-α | Y | Crohn's disease, rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis
Cetrelimab[5] |  | mab | human | PD-1 |  | cancer
Cetuximab[31] | Erbitux | mab | chimeric | Epidermal growth factor receptor (EGFR) | Y | metastatic colorectal cancer and head and neck cancer
Cibisatamab[5] |  | mab | humanized | CEACAM5 |  | cancer
Cilgavimab[28] |  | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Emergency Use Authorization (EUA) when used with tixagevimab[47] | COVID-19
Cirmtuzumab[31] |  |  | humanized | ROR1 |  | chronic lymphocytic leukemia
Citatuzumab bogatox[48] |  | Fab | humanized | EpCAM |  | ovarian cancer and other solid tumors
Cixutumumab[31] |  | mab | human | IGF-1 receptor (CD221) |  | solid tumors
Clazakizumab[49] |  | mab | humanized | IL-6 |  | rheumatoid arthritis
Clenoliximab[31] |  | mab | chimeric | CD4 |  | rheumatoid arthritis
Clivatuzumab tetraxetan[31] | hPAM4-Cide | mab | humanized | MUC1 |  | pancreatic cancer
Codrituzumab[4] |  | mab | humanized | glypican 3 |  | cancer
Cofetuzumab pelidotin[26] |  | mab | humanized | PTK7 |  | cancer
Coltuximab ravtansine[4] |  | mab | chimeric | CD19 |  | cancer
Conatumumab[48] |  | mab | human | TRAIL-R2 |  | cancer
Concizumab[50] | Alhemo | mab | humanized | tissue factor pathway inhibitor (TFPI) | Y | bleeding with hemophilia
Cosfroviximab[27] | ZMapp | mab | chimeric | ebolavirus glycoprotein |  | Ebola virus
Crenezumab[31] |  | mab | humanized | β-amyloid (1-40 and 1-42) |  | Alzheimer's disease
Crizanlizumab[22] | Adakveo | mab | humanized | selectin P | Y | sickle-cell disease
Crotedumab[40] |  | mab | human | glucagon receptor (GCGR) |  | diabetes
CR6261 |  | mab | human | Hemagglutinin (influenza) |  | infectious disease/influenza A
Cusatuzumab[5] |  | mab | humanized | CD70 |  | cancer
Dacetuzumab[13] |  | mab | humanized | CD40 |  | hematologic cancers
Daclizumab[51] | Zenapax | mab | humanized | CD25 (α chain of IL-2 receptor) | Y | prevention of organ transplant rejections, multiple sclerosis
Dalotuzumab |  | mab | humanized | IGF-1 receptor (CD221) |  | cancer etc.
Dapirolizumab pegol[52] |  | mab | humanized | CD154 (CD40L) |  |
Daratumumab[53] | Darzalex | mab | human | CD38 | Y[54] | multiple myeloma
Dectrekumab[25] |  | mab | human | IL-13 |  |
Demcizumab |  | mab | humanized | DLL4 |  | cancer
Denintuzumab mafodotin[6] |  | mab | humanized | CD19 |  | cancer
Denosumab[55] | Prolia | mab | human | RANKL | Y | osteoporosis, bone metastases etc.
Depatuxizumab mafodotin[22] |  | mab | chimeric/
humanized | EGFR |  | glioblastoma
Derlotuximab biotin |  | mab | chimeric | histone complex |  | recurrent glioblastoma multiforme
Detumomab |  | mab | mouse | B-lymphoma cell |  | lymphoma
Dezamizumab[22] |  | mab | humanized | serum amyloid P component |  |
Dinutuximab | Unituxin | mab | chimeric | GD2 ganglioside | Y | neuroblastoma
Dinutuximab beta | Qarziba | mab | chimeric | GD2 ganglioside | Y | neuroblastoma
Diridavumab |  | mab | human | Hemagglutinin (influenza) |  | influenza A
Divozilimab[28] | Ivlizi | mab | humanized | CD20 | Y (Russia)[56] | multiple sclerosis
Domagrozumab[40] |  | mab | humanized | GDF-8 |  | Duchenne muscular dystrophy
Donanemab |  | mab | humanized | Amyloid beta |  | Alzheimer's disease
Dorlimomab aritox[57] |  | F(ab')2 | mouse |  |  |
Dostarlimab[58] | Jemperli | mab | humanized | PCDP1 | Y | endometrial cancer
Drozitumab |  | mab | human | DR5 |  | cancer etc.
DS-8201 |  |  | humanized | HER2 |  | gastric or gastroesophageal junction adenocarcinoma
Duligotuzumab[15] |  | mab | humanized | ERBB3 (HER3) |  | testicular cancer
Dupilumab[39] | Dupixent | mab | human | IL-4Rα | Y | atopic dermatitis, asthma, nasal polyps
Durvalumab[25] | Imfinzi | mab | human | PD-L1 | Y | cancer
Dusigitumab |  | mab | human | IGF-2 |  | B-cell malignancies
Duvortuxizumab[27] |  | scFv | chimeric/
humanized | CD19, CD3E |  | cancer
Ecromeximab[21] |  | mab | chimeric | GD3 ganglioside |  | malignant melanoma
Eculizumab[21] | Soliris | mab | humanized | C5 | Y | paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Edobacomab |  | mab | mouse | endotoxin |  | sepsis caused by Gram-negative bacteria
Edrecolomab | Panorex | mab | mouse | EpCAM |  | colorectal carcinoma
Efalizumab[7] | Raptiva | mab | humanized | LFA-1 (CD11a) |  | psoriasis (blocks T-cell migration)
Efungumab[1] | Mycograb | scFv | human | Hsp90 |  | invasive Candida infection
Eldelumab[4] |  | mab | human | CXCL10 (IP-10) |  | Crohn's disease, ulcerative colitis
Elezanumab[22] |  | mab | human | repulsive guidance molecule A (RGMA) |  | spinal cord injury and multiple sclerosis
Elgemtumab[25] |  | mab | human | ERBB3 (HER3) |  | cancer
Elotuzumab | Empliciti | mab | humanized | SLAMF7 | Y | multiple myeloma
Elsilimomab |  | mab | mouse | IL-6 |  |
Emactuzumab[6] |  | mab | humanized | CSF1R |  | cancer
Emapalumab[22] | Gamifant | mab | human | IFN-γ | Y | hemophagocytic lymphohistiocytosis
Emibetuzumab |  | mab | humanized | HGFR |  | cancer
Emicizumab[12] | Hemlibra | BsAb | humanized | activated F9, F10 | Y | haemophilia A
Enapotamab vedotin[5] |  | mab | human | AXL |  | cancer
Enavatuzumab |  | mab | humanized | TWEAK receptor |  | cancer etc.
Enfortumab vedotin[4] | Padcev | mab | human | nectin-4 | Y[59] | urothelial cancer
Enlimomab pegol[60] |  | mab | mouse | ICAM-1 (CD54) |  |
Enoblituzumab[22] |  | mab | humanized | CD276 |  | cancer
Enokizumab |  | mab | humanized | IL-9 |  | asthma
Enoticumab[15] |  | mab | human | DLL4 |  |
Ensituximab |  | mab | chimeric | MUC5AC |  | cancer
Epcoritamab | Epkinly[61][62] | BiTE | humanized | CD3, CD20 | Y | diffuse large B-cell lymphoma
Epitumomab cituxetan[63] |  | mab | mouse | episialin |  |
Epratuzumab |  | mab | humanized | CD22 |  | cancer, systemic lupus erythematosus (SLE)
Eptinezumab[22] | Vyepti | mab | humanized | calcitonin gene-related peptide | Y[64] | migraine
Erenumab[22] | Aimovig | mab | human | calcitonin gene-related peptide receptor (CGRP) | Y | migraine
Erlizumab[65] |  | F(ab')2 | humanized | ITGB2 (CD18) |  | heart attack, stroke, traumatic shock
Ertumaxomab[30] | Rexomun | 3funct | rat/mouse hybrid | HER2/neu, CD3 | Y | breast cancer etc.
Etaracizumab | Abegrin | mab | humanized | integrin αvβ3 | Y | melanoma, prostate cancer, ovarian cancer etc.
Etesevimab[28] |  | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Emergency Use Authorization (EUA) when used with bamlanivimab[29] | COVID-19
Etigilimab[5] |  | mab | humanized | TIGIT |  |
Etrolizumab[16] |  | mab | humanized | integrin β7 |  | inflammatory bowel disease
Evinacumab | Evkeeza | mab | human | angiopoietin 3 | Y | dyslipidemia
Evolocumab[39] | Repatha | mab | human | PCSK9 | Y | hypercholesterolemia
Exbivirumab[66] |  | mab | human | hepatitis B surface antigen |  | hepatitis B
Fanolesomab[17] | NeutroSpec | mab | mouse | CD15 |  | appendicitis (diagnosis)
Faralimomab |  | mab | mouse | IFN receptor |  |
Faricimab[67] | Vabysmo | mab | humanized | VEGF-A and Ang-2 | Y | angiogenesis, ocular vascular diseases
Farletuzumab |  | mab | humanized | folate receptor 1 |  | ovarian cancer
Fasinumab |  | mab | human | nerve growth factor (NGF) |  | acute sciatic pain
FBTA05[68][69] | Lymphomun | 3funct | rat/mouse hybrid | CD20 |  | chronic lymphocytic leukaemia
Felvizumab |  | mab | humanized | respiratory syncytial virus |  | respiratory syncytial virus infection
Fezakinumab[70][71] |  | mab | human | IL-22 |  | rheumatoid arthritis, psoriasis
Fibatuzumab[72] |  | mab | humanized | ephrin receptor A3 |  |
Ficlatuzumab |  | mab | humanized | Hepatocyte growth factor (HGF) |  | cancer etc.
Figitumumab |  | mab | human | IGF-1 receptor (CD221) |  | adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab[6] |  | mab | human | Hemagglutinin (influenza) |  |
Flanvotumab |  | mab | human | TYRP1 (glycoprotein 75) |  | melanoma
Fletikumab |  | mab | human | IL-20 |  | rheumatoid arthritis
Flotetuzumab[5] |  | di-scFv | humanized | IL-3 receptor |  | hematological malignancies
Fontolizumab[21] | HuZAF | mab | humanized | IFN-γ |  | Crohn's disease etc.
Foralumab[73] |  | mab | human | CD3E |  |
Foravirumab[48] |  | mab | human | rabies virus glycoprotein |  | rabies (prophylaxis)
Fremanezumab[22] | Ajovy | mab | humanized | calcitonin gene-related peptide alpha and beta | Y | migraine
Fresolimumab[53] |  | mab | human | TGF-β |  | idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Frovocimab[58] |  | mab | humanized | PCSK9 |  | hypercholesterolemia
Frunevetmab[74] | Solensia[75] | mab | veterinary | nerve growth factor (NGF)[75] | Y | pain associated with osteoarthritis in cats[75]
Fulranumab |  | mab | human | nerve growth factor (NGF) |  | pain
Futuximab[15] |  | mab | chimeric | Epidermal growth factor receptor (EGFR) |  | cancer
Galcanezumab[40] | Emgality | mab | humanized | calcitonin | Y | migraine
Galiximab |  | mab | chimeric | CD80 |  | B-cell lymphoma
Gancotamab |  | scFv | human | HER2/neu |  | cancer
Ganitumab |  | mab | human | IGF-1 receptor (CD221) |  | cancer
Gantenerumab[42] |  | mab | human | β-amyloid (1-40 and 1-42) |  | Alzheimer's disease
Gatipotuzumab[27] |  | mab | humanized | MUC1 |  | cancer
Gavilimomab[65] |  | mab | mouse | CD147 (basigin) |  | graft versus host disease
Gedivumab[27] |  | mab | human | Hemagglutinin (influenza) |  |
Gemtuzumab ozogamicin[22] | Mylotarg | mab | humanized | CD33 | Y | acute myelogenous leukemia
Gevokizumab |  | mab | humanized | IL-1β |  | diabetes etc.
Gilvetmab[27] |  | mab | veterinary | PCDC1 |  |
Gimsilumab[26] |  | mab | human | CSF2 |  | rheumatoid arthritis
Girentuximab[53] | Rencarex | mab | chimeric | carbonic anhydrase 9 (CA-IX) |  | clear cell renal cell carcinoma[76]
Glembatumumab vedotin[37][77] |  | mab | human | GPNMB |  | melanoma, breast cancer
Glofitamab[61] | Columvi[78] | BsAb | humanized | CD20, CD3 | Y[78] | diffuse large B-cell lymphoma[78]
Golimumab[66] | Simponi | mab | human | TNF-α | Y | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab |  | mab | chimeric | CD23 (IgE receptor) |  | allergic asthma
Gosuranemab |  | mab | humanized | tau protein |  | progressive supranuclear palsy
Guselkumab | Tremfya | mab | human | IL-23 | Y | psoriasis
Ianalumab[26] |  | mab | human | BAFF-R |  | autoimmune hepatitis
Ibalizumab[42] | Trogarzo | mab | humanized | CD4 | Y | HIV infection
Sintilimab |  |  | human | PD-1 |  | squamous cell non-small cell lung cancer
Ibritumomab tiuxetan | Zevalin | mab | mouse | CD20 | Y | non-Hodgkin's lymphoma
Icrucumab |  | mab | human | VEGFR-1 |  | cancer etc.
Idarucizumab[4] | Praxbind | mab | humanized | dabigatran | Y | reversal of anticoagulant effects of dabigatran
Ifabotuzumab[22] |  | mab | humanized | EPHA3 |  | glioblastoma multiforme[79]
Igovomab | Indimacis-125 | F(ab')2 | mouse | CA-125 |  | ovarian cancer (diagnosis)
Iladatuzumab vedotin[26] |  | mab | humanized | CD79B |  | cancer
Imalumab[6] |  | mab | human | macrophage migration inhibitory factor (MIF) |  | cancer
Imaprelimab[5] |  | mab | humanized | melanoma cell adhesion molecule (MCAM) |  |
Imciromab | Myoscint | mab | mouse | cardiac myosin | Y | cardiac imaging
Imdevimab[28] |  | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Yes when used with casirivimab[44][45] | COVID-19
Imgatuzumab[15] |  | mab | humanized | Epidermal growth factor receptor (EGFR) |  | cancer
Inclacumab[43] |  | mab | human | selectin P |  | cardiovascular disease
Indatuximab ravtansine[41] |  | mab | chimeric | SDC1 |  | cancer
Indusatumab vedotin[25] |  | mab | human | GUCY2C |  | cancer
Inebilizumab[12] | Uplizna | mab | humanized | CD19 | Y[80] | cancer, systemic sclerosis, multiple sclerosis
Infliximab | Remicade | mab | chimeric | TNF-α | Y | rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[81][82] |  | mab | human | CD51 |  | solid tumors (prostate cancer, melanoma)
Inolimomab |  | mab | mouse | CD25 (α chain of IL-2 receptor) |  | graft versus host disease
Inotuzumab ozogamicin[38] | Besponsa | mab | humanized | CD22 | Y | Acute lymphoblastic leukemia (ALL)
Ipilimumab[55] | Yervoy | mab | human | CD152 | Y | melanoma
Iomab-B |  |  | mouse | CD45 |  | ablation of bone marrow
Iratumumab[55] |  | mab | human | CD30 (TNFRSF8) |  | Hodgkin's lymphoma
Isatuximab | Sarclisa | mab | chimeric | CD38 | Y | multiple myeloma
Iscalimab[5] |  | mab | human | CD40 |  |
Istiratumab[26] |  | mab | human | IGF-1 receptor (CD221) |  | advanced solid tumors
Itolizumab[73] | Alzumab | mab | humanized | CD6 | Y | psoriasis
Ixekizumab | Taltz | mab | humanized | IL-17A | Y | autoimmune diseases
Keliximab |  | mab | chimeric | CD4 |  | chronic asthma
Labetuzumab[7] | CEA-Cide | mab | humanized | Carcinoembryonic antigen (CEA) |  | colorectal cancer
Lacnotuzumab[27] |  | mab | humanized | CSF1, macrophage colony stimulating factor (MCSF) |  | cancer
Ladiratuzumab vedotin[26] |  | mab | humanized | LIV-1 |  | cancer
Lampalizumab[15] |  | Fab | humanized | Complement factor D (CFD) |  | geographic atrophy secondary to age-related macular degeneration
Lanadelumab[40] | Takhzyro | mab | human | kallikrein | Y | angioedema
Landogrozumab[12] |  | mab | humanized | GDF-8 |  | muscle wasting disorders
Laprituximab emtansine[40] |  | mab | chimeric | epidermal growth factor receptor (EGFR) |  |
Larcaviximab[27] |  | mab | chimeric | ebolavirus glycoprotein |  | Ebola virus
Lebrikizumab |  | mab | humanized | IL-13 |  | asthma
Lecanemab[83] | Leqembi | mab | humanized | β-amyloid | Y[84] | Alzheimer's disease
Lemalesomab[65] |  | mab | mouse | NCA-90 (granulocyte antigen) |  | diagnostic agent
Lendalizumab[40] |  | mab | humanized | C5 |  |
Lenvervimab[5] |  | mab | humanized | hepatitis B surfage antigen |  | hepatitis B
Lenzilumab[6] |  | mab | human | CSF2 |  | chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia
Lerdelimumab[17] |  | mab | human | TGF-β2 |  | reduction of scarring after glaucoma surgery
Leronlimab[5] |  | mab | humanized | CCR5 |  | breast cancer, HIV
Lesofavumab[27] |  | mab | human | Hemagglutinin (influenza) |  |
Letolizumab[27] |  | scFv | humanized | tumor necrosis factor related activation protein (TRAP) |  | inflammatory diseases
Lexatumumab[1] |  | mab | human | TRAIL-R2 |  | cancer
Libivirumab[66] |  | mab | human | hepatitis B surface antigen |  | hepatitis B
Lifastuzumab vedotin |  | mab | humanized | phosphate-sodium co-transporter |  | cancer
Ligelizumab[15] |  | mab | humanized | IGHE |  | severe asthma, chronic spontaneous urticaria
Loncastuximab tesirine[85][72] | Zynlonta | mab | chimeric | CD19 | Y | relapsed or refractory large B-cell lymphoma
Losatuxizumab vedotin[27] |  | mab | chimeric/
humanized | epidermal growth receptor factor (EGRF), ERBB1 HER1 |  | cancer
Lilotomab satetraxetan[25] |  | mab | mouse | CD37 |  | cancer
Lintuzumab |  | mab | humanized | CD33 |  | cancer
Lirilumab[15] |  | mab | human | KIR2D |  | solid and hematological cancers
Lodelcizumab[39] |  | mab | humanized | PCSK9 |  | hypercholesterolemia
Lokivetmab[25] | Cytopoint[86] | mab | veterinary | Canis lupus familiaris IL31 | Y | clinical signs of atopic dermatitis in dogs[86]
Lorvotuzumab mertansine |  | mab | humanized | CD56 |  | cancer
Lucatumumab[13] |  | mab | human | CD40 |  | multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol[6] |  | mab | humanized | CD28 |  | autoimmune diseases
Lumiliximab[9] |  | mab | chimeric | CD23 (IgE receptor) |  | chronic lymphocytic leukemia
Lumretuzumab[6] |  | mab | humanized | ERBB3 (HER3) |  | cancer
Lupartumab[22] |  | mab | human |  |  |
Lupartumab amadotin[22] |  | mab | human | LYPD3 |  |
Lutikizumab[22] |  | mab | humanized | IL-1α |  |
Maftivimab |  | mab | human |  |  | part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Mapatumumab[30] |  | mab | human | TRAIL-R1 |  | cancer
Margetuximab | Margenza[87] | mab | humanized | HER2 | Y | breast cancer
Marstacimab |  | mab | human | tissue factor pathway inhibitor (TFPI) |  | bleeding with hemophilia
Maslimomab |  |  | mouse | T-cell receptor |  |
Mavrilimumab[37] |  | mab | human | GMCSF receptor α-chain |  | rheumatoid arthritis
Matuzumab[24] |  | mab | humanized | Epidermal growth factor receptor (EGFR) |  | colorectal, lung and stomach cancer
Mepolizumab[46] | Bosatria | mab | humanized | IL-5 | Y | asthma and white blood cell diseases
Metelimumab[24] |  | mab | human | TGF-β1 |  | systemic scleroderma
Milatuzumab[13] |  | mab | humanized | CD74 |  | multiple myeloma and other hematological malignancies
Minretumomab |  | mab | mouse | TAG-72 |  | tumor detection (and therapy?)
Mirikizumab[85] | Omvoh | mab | humanized | IL-23 | Y | ulcerative colitis
Mirvetuximab soravtansine[12] | Elahere | mab | chimeric | folate receptor alpha | Y[88] | ovarian cancer
Mitumomab |  | mab | mouse | GD3 ganglioside |  | small cell lung carcinoma
Modotuximab |  | mab | chimeric | EGFR extracellular domain III |  | cancer
Mogamulizumab[16] | Poteligeo | mab | humanized | CCR4 | Y | adult T-cell leukemia/lymphoma
Monalizumab[12] |  | mab | humanized | NKG2A |  | rheumatoid arthritis, gynecologic malignancies, and other cancers
Morolimumab[89] |  | mab | human | Rhesus factor |  |
Mosunetuzumab[85] | Lunsumio | BiTE | humanized | CD3E, MS4A1, CD20 | Y[90] | follicular lymphoma
Motavizumab[1] | Numax | mab | humanized | respiratory syncytial virus |  | respiratory syncytial virus (prevention)
Moxetumomab pasudotox | Lumoxiti | mab | mouse | CD22 | Y | hairy cell leukemia
Muromonab-CD3[91][92] | Orthoclone OKT3 | mab | mouse | CD3 |  | prevention of organ transplant rejections
Nacolomab tafenatox |  | Fab | mouse | C242 antigen |  | colorectal cancer
Namilumab[16] |  | mab | human | CSF2 |  |
Naptumomab estafenatox[93] |  | Fab | mouse | 5T4 |  | non-small cell lung carcinoma, renal cell carcinoma
Naratuximab emtansine[40] |  | mab | chimeric | CD37 |  |
Narnatumab |  | mab | human | MST1R (aka RON) |  | cancer
Natalizumab[89] | Tysabri | mab | humanized | integrin α4 | Y | multiple sclerosis, Crohn's disease
Navicixizumab[40] |  | mab | chimeric/
humanized | DLL4 and VEGFA |  | cancer
Navivumab[12] |  | mab | human | Hemagglutinin (influenza) |  |
Naxitamab | Danyelza |  | humanized | c-Met | Y | high-risk neuroblastoma and refractory osteomedullary disease
Nebacumab |  | mab | human | endotoxin |  | sepsis
Necitumumab[94] | Portrazza | mab | human | Epidermal growth factor receptor (EGFR) | Y | non-small cell lung carcinoma
Nemolizumab[25] |  | mab | humanized | IL-31 receptor A |  | eczema[95]
NEOD001 |  |  | humanized | amyloid |  | primary systemic amyloidosis
Nerelimomab |  | mab | mouse | TNF-α |  |
Nesvacumab |  | mab | human | angiopoietin 2 |  | cancer
Netakimab[5] | Efleira | mab | humanized | IL-17A | Y (Russia)[96] | plaque psoriasis, psoriatic arthritis, ankylosing spondylitis
Nimotuzumab[55][97] | BioMab-EGFR, Theracim, Theraloc | mab | humanized | epidermal growth factor receptor (EGFR) | Y | squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nirsevimab |  | mab | human | RSV fusion glycoprotein |  | respiratory syncytial virus
Nivolumab[6] | Opdivo | mab | human | PD-1 | Y | cancer
Nofetumomab merpentan | Verluma | Fab | mouse |  |  | cancer (diagnosis)
Obiltoxaximab | Anthim | mab | chimeric | Bacillus anthracis anthrax | Y | Bacillus anthracis spores
Obinutuzumab | Gazyva | mab | humanized | CD20 | Y | chronic lymphatic leukemia
Ocaratuzumab |  | mab | humanized | CD20 |  | cancer
Ocrelizumab[98] | Ocrevus | mab | humanized | CD20 | Y | multiple sclerosis
Odesivimab |  | mab | human |  |  | part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Odulimomab |  | mab | mouse | LFA-1 (CD11a) |  | prevention of organ transplant rejections, immunological diseases
Ofatumumab[30] | Arzerra, Kesimpta[99] | mab | human | CD20 | Y | chronic lymphocytic leukemia, multiple sclerosis[99]
Olaratumab | Lartruvo | mab | human | PDGFRA | Y | cancer
Oleclumab[27] |  | mab | human | 5'-nucleotidase |  | pancreatic and colorectal cancer
Olendalizumab[27] |  | mab | humanized | complement C5a |  | systemic lupus erythematosus, lupus nephritis, acute graft-versus-hose disease
Olokizumab[73] |  | mab | humanized | IL-6 |  | rheumatoid arthritis
Omalizumab[65] | Xolair | mab | humanized | IgE Fc region | Y | allergic asthma, chronic spontaneous urticaria
Omburtamab[58] |  | mab | mouse | CD276 |  | cancer
OMS721 |  |  | human | MASP-2 |  | atypical hemolytic uremic syndrome
Onartuzumab |  | Fab | humanized | human scatter factor receptor kinase |  | cancer
Ontuxizumab |  | mab | chimeric/
humanized | TEM1 |  | cancer
Onvatilimab[5] |  | mab | human | VISTA (protein) (VSIR) |  |
Opicinumab |  | mab | human | LINGO-1 |  | multiple sclerosis
Oportuzumab monatox[94] | Vicinium | scFv | humanized | EpCAM |  | bladder cancer
Oregovomab[17] | OvaRex | mab | mouse | CA-125 |  | ovarian cancer
Orticumab[15] |  | mab | human | oxLDL |  |
Otelixizumab[13] |  | mab | chimeric/
humanized | CD3 |  | diabetes mellitus type 1
Otilimab |  | mab | human | GMCSF |  | osteoarthritis, rheumatoid arthritis
Otlertuzumab |  | mab | humanized | CD37 |  | cancer
Oxelumab[41] |  | mab | human | OX-40 |  | asthma
Ozanezumab |  | mab | humanized | NOGO-A |  | ALS and multiple sclerosis
Ozoralizumab[41] |  | mab | humanized | TNF-α |  | inflammation
Pagibaximab[30] |  | mab | chimeric | lipoteichoic acid |  | sepsis (Staphylococcus)
Palivizumab | Synagis, Abbosynagis | mab | humanized | F protein of respiratory syncytial virus | Y | respiratory syncytial virus (prevention)
Pamrevlumab[12] |  | mab | human | connective tissue growth factor (CTGF) |  | idiopathic pulmonary fibrosis (IPF), pancreatic cancer
Panitumumab[66] | Vectibix | mab | human | epidermal growth factor receptor (EGFR) | Y | colorectal cancer
Pankomab |  | mab | humanized | tumor specific glycosylation of MUC1 |  | ovarian cancer
Panobacumab[94] |  | mab | human | Pseudomonas aeruginosa |  | Pseudomonas aeruginosa infection
Parsatuzumab[15] |  | mab | humanized | EGFL7 |  | cancer
Pascolizumab[21] |  | mab | humanized | IL-4 |  | asthma
Pasotuxizumab[6] |  | mab | chimeric/
humanized | folate hydrolase |  | cancer
Pateclizumab[41] |  | mab | humanized | lymphotoxin alpha (LTA) |  | TNF
Patritumab[43] |  | mab | human | ERBB3 (HER3) |  | cancer
PDR001 |  |  | humanized | PD-1 |  | melanoma
Pembrolizumab[52] | Keytruda | mab | humanized | PD-1 | Y[100] | melanoma and other cancers
Pemtumomab | Theragyn |  | mouse | MUC1 |  | cancer
Perakizumab[15] |  | mab | humanized | IL-17A |  | arthritis
Pertuzumab | Perjeta | mab | humanized | HER2/neu | Y | cancer
Pexelizumab[17] |  | scFv | humanized | C5 |  | reduction of side effects of cardiac surgery
Pidilizumab[39] |  | mab | humanized | PD-1 |  | cancer and infectious diseases
Pinatuzumab vedotin[39] |  | mab | humanized | CD22 |  | cancer
Pintumomab |  | mab | mouse | adenocarcinoma antigen |  | adenocarcinoma (imaging)
Placulumab[15] |  | mab | human | TNF |  | pain and inflammatory diseases
Pozelimab[34] | Veopoz | mab | human | C5 | Y | CHAPLE disease
Prezalumab[40] |  | mab | human | TNF |  |
Plozalizumab[12] |  | mab | humanized | CCR2 |  | diabetic nephropathy and arteriovenous graft patency
Pogalizumab[40] |  | mab | humanized | tumor necrosis factor receptor (TNFR) superfamily member 4 |  |
Polatuzumab vedotin[50][4] | Polivy | mab | humanized | CD79B | Y | diffuse large B-cell lymphoma
Ponezumab |  | mab | humanized | β-amyloid |  | Alzheimer's disease
Porgaviximab[27] |  | mab | chimeric | Zaire ebolavirus glycoprotein |  | Ebola virus disease
Prasinezumab[26] |  | mab | humanized | Alpha-synuclein |  | Parkinson's disease
Prezalizumab[40] |  | mab | humanized | inducible T-cell co-stimulatory ligand (ICOSL) |  |
Priliximab |  | mab | chimeric | CD4 |  | Crohn's disease, multiple sclerosis
Pritoxaximab[39] |  | mab | chimeric | E. coli shiga toxin type-1 |  |
Pritumumab |  | mab | human | vimentin |  | brain cancer
PRO 140 |  |  | humanized | CCR5 |  | HIV infection
Quilizumab[43] |  | mab | humanized | IGHE |  | asthma
Racotumomab[94] | Vaxira | mab | mouse | NGNA ganglioside | Y | non-small cell lung cancer
Radretumab[16] |  | mab | human | fibronectin extra domain-B |  | cancer
Rafivirumab[48] |  | mab | human | rabies virus glycoprotein |  | rabies (prophylaxis)
Ralpancizumab |  | mab | humanized | PCSK9 |  | dyslipidemia
Ramucirumab | Cyramza | mab | human | VEGFR2 | Y | solid tumors
Ranevetmab |  | mab | veterinary | NGF |  | osteoarthritis in dogs
Ranibizumab[9] | Lucentis | Fab | humanized | VEGF-A | Y | macular degeneration (wet form)
Raxibacumab[38] |  | mab | human | anthrax toxin, protective antigen | Y | anthrax (prophylaxis and treatment)
Ravagalimab[5] |  | mab | humanized | CD40 |  | Crohn's disease
Ravulizumab[26] | Ultomiris | mab | humanized | C5 | Y | paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Refanezumab |  | mab | humanized | myelin-associated glycoprotein |  | recovery of motor function after stroke
Regavirumab |  | mab | human | cytomegalovirus glycoprotein B |  | cytomegalovirus infection
Regdanvimab[28] | Regkirona[101] | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Y[101] | COVID-19
Relatlimab |  | mab | human | LAG3 |  | melanoma
Remtolumab[22] |  | mab | human | IL-17A, TNF |  |
Reslizumab[7] | Cinqair | mab | humanized | IL-5 | Y | inflammations of the airways, skin and gastrointestinal tract
Retifanlimab[61] | Zynyz[102] | mab | humanized | PD-1 | Y | Merkel cell carcinoma
Rilotumumab |  | mab | human | hepatocyte growth factor (HGF) |  | solid tumors
Rinucumab |  | mab | human | PDGFRB |  | neovascular age-related macular degeneration
Risankizumab[12] | Skyrizi | mab | humanized | IL-23A | Y | Crohn's disease, psoriasis, psoriatic arthritis, and asthma
Rituximab | MabThera, Rituxan | mab | chimeric | CD20 | Y[103] | lymphomas, leukemias, some autoimmune disorders
Rivabazumab pegol[12] |  | mab | humanized | Pseudomonas aeruginosa type III secretion system |  |
Robatumumab |  | mab | human | IGF-1 receptor (CD221) |  | cancer
Rmab | RabiShield |  | human | rabies virus G glycoprotein | Y | post-exposure prophylaxis of rabies
Roledumab[73] |  | mab | human | RHD (gene) (RHD) |  | Rh disease
Romilkimab[5] |  | mab | chimeric/
humanized | IL-13 |  |
Romosozumab | Evenity | mab | humanized | sclerostin | Y | osteoporosis
Rontalizumab[53] |  | mab | humanized | IFN-α |  | systemic lupus erythematosus
Rosmantuzumab[22] |  | mab | humanized | root plate-specific spondin 3 |  | cancer
Rovalpituzumab tesirine[12] |  | mab | humanized | DLL3 |  | small cell lung cancer
Rovelizumab[46] | LeukArrest | mab | humanized | CD11, CD18 | Y | haemorrhagic shock etc.
Rozanolixizumab[22] | Rystiggo | mab | chimeric/
humanized | FCGRT | Y[104] | myasthenia gravis
Ruplizumab[14] | Antova | mab | humanized | CD154 (CD40L) | Y | rheumatic diseases
SA237 |  |  | humanized | IL-6 receptor |  | neuromyelitis optica and neuromyelitis optica spectrum disorders
Sacituzumab govitecan[22] | Trodelvy | mab | humanized | TROP-2 | Y[105] | triple-negative breast cancer
Samalizumab[41] |  | mab | humanized | CD200 |  | cancer
Samrotamab vedotin[5] |  | mab | chimeric/
humanized | LRRC15 |  | cancer
Sarilumab[43] | Kevzara | mab | human | IL-6 | Y | rheumatoid arthritis, ankylosing spondylitis
Satralizumab[74] | Enspryng | mab | humanized | IL-6 receptor | Y | neuromyelitis optica
Satumomab pendetide |  | mab | mouse | TAG-72 |  | cancer (diagnosis)
Secukinumab | Cosentyx | mab | human | IL-17A | Y | uveitis, rheumatoid arthritis psoriasis
Selicrelumab[27] |  | mab | human | CD40 |  |
Seribantumab[39] |  | mab | human | ERBB3 (HER3) |  | cancer
Setoxaximab[39] |  | mab | chimeric | E. coli shiga toxin type-2 |  |
Setrusumab[26] |  | mab | human | sclerostin (SOST) |  |
Sevirumab |  |  | human | cytomegalovirus |  | cytomegalovirus infection
Sibrotuzumab |  | mab | humanized | FAP (gene) (FAP) |  | cancer
SGN-CD19A |  | mab | humanized | CD19 |  | acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SHP647 |  |  | human | mucosal addressin cell adhesion molecule |  | Crohn's disease
Sifalimumab[16] |  | mab | human | IFN-α |  | systemic lupus erythematosus (SLE), dermatomyositis, polymyositis
Siltuximab | Sylvant | mab | chimeric | IL-6 | Y | cancer
Simtuzumab[15] |  | mab | humanized | LOXL2 |  | fibrosis
Siplizumab[21] |  | mab | humanized | CD2 |  | psoriasis, graft-versus-host disease (prevention)
Sirtratumab vedotin[26] |  | mab | human | SLITRK6 |  | cancer
Sirukumab |  | mab | human | IL-6 |  | rheumatoid arthritis
Sofituzumab vedotin |  | mab | humanized | CA-125 |  | ovarian cancer
Solanezumab[94] |  | mab | humanized | β-amyloid |  | Alzheimer's disease
Solitomab[43] |  | BiTE | mouse | EpCAM |  | gastrointestinal, lung, and other cancers
Sonepcizumab[106] |  |  | humanized | sphingosine-1-phosphate |  | choroidal and retinal neovascularization
Sontuzumab[97] |  | mab | humanized | episialin |  |
Sotrovimab[28] | Xevudy | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Y[107][108] | COVID-19
Spartalizumab[26] |  | mab | humanized | PD-1 |  | melanoma
Spesolimab[109] | Spevigo | mab | humanized | Interleukin 36 receptor (IL1RL2/IL1RAP) | Y | generalized pustular psoriasis (GPP)
Stamulumab[98] |  | mab | human | myostatin |  | muscular dystrophy
Sulesomab | LeukoScan | Fab' | mouse | NCA-90 (granulocyte antigen) |  | osteomyelitis (imaging)
Suptavumab[22] |  | mab | human | RSVFR |  | medically attended lower respiratory disease
Sutimlimab[67] | Enjaymo | mab | chimeric/
humanized | complement component 1s (C1s) | Y | cold agglutinin disease
Suvizumab[37] |  | mab | humanized | HIV-1 |  | viral infections
Suvratoxumab[27] |  | mab | human | Staphylococcus aureus alpha toxin |  | nosocomial pneumonia
Tabalumab[41] |  | mab | human | B-cell activating factor (BAFF) |  | B-cell cancers
Tacatuzumab tetraxetan | AFP-Cide | mab | humanized | alpha-fetoprotein |  | cancer
Tadocizumab[97] |  | Fab | humanized | integrin αIIbβ3 |  | percutaneous coronary intervention
Tafasitamab[46] | Monjuvi | mab | humanized
(from mouse) | CD19 | Y | relapsed or refractory diffuse large B-cell lymphoma
Talacotuzumab[26] |  | mab | humanized | CD123 |  | leukemia etc.
Talizumab[36] |  | mab | humanized | IgE |  | allergic reaction
Talquetamab | Talvey | BsAb | humanized | GPRC5D, CD3 | Y | relapsed or refractory multiple myeloma
Tamtuvetmab[40] | Tactress | mab | veterinary | CD52 |  |
Tanezumab[48] |  | mab | humanized | nerve growth factor (NGF) |  | pain
Taplitumomab paptox[65] |  | mab | mouse | CD19 |  | cancer[citation needed]
Tarextumab |  | mab | human | Notch receptor |  | cancer
Tavolimab |  | mab | chimeric/
humanized | CD134 |  | cancer
Teclistamab | Tecvayli[34] | BsAb | human | B-cell maturation antigen (BCMA), CD3 | Y[110][111] | relapsed or refractory multiple myeloma
Tefibazumab[38] | Aurexis | mab | humanized | clumping factor A |  | Staphylococcus aureus infection
Telimomab aritox |  | Fab | mouse |  |  |
Telisotuzumab[22] |  | mab | humanized | HGFR |  | cancer
Telisotuzumab vedotin[22] |  | mab | humanized | HGFR |  | cancer
Tenatumomab[13] |  | mab | mouse | tenascin C |  | cancer
Teneliximab[21] |  | mab | chimeric | CD40 |  | autoimmune diseases and prevention of organ transplant rejection
Teplizumab[42] | Tzield | mab | humanized | CD3 | Y | diabetes mellitus type 1
Tepoditamab[5] |  | mab | human | dendritic cell-associated lectin 2 |  | cancer
Teprotumumab | Tepezza | mab | human | IGF-1 receptor (CD221) | Y | thyroid eye disease
Tesidolumab[25] |  | mab | human | C5 |  |
Tetulomab |  | mab | humanized | CD37 |  | cancer[112]
Tezepelumab[12] | Tezspire | mab | human | thymic stromal lymphopoietin (TSLP) | Y[113] | asthma
TGN1412 |  |  | humanized | CD28 |  | chronic lymphocytic leukemia, rheumatoid arthritis
Tibulizumab[26] |  | mab | humanized | B-cell activating factor (BAFF) |  | autoimmune disorders
Tildrakizumab | Ilumya | mab | humanized | IL-23 | Y | immunologically mediated inflammatory disorders
Tigatuzumab[13] |  | mab | humanized | TRAIL-R2 |  | cancer
Timigutuzumab[27] |  | mab | humanized | HER2 |  | cancer
Timolumab[40] |  | mab | human | AOC3 |  |
tiragolumab[26] |  | mab | human |  |  |
Tiragotumab[26] |  | mab | human | TIGIT |  | cancer
Tislelizumab[26] |  | mab | humanized | PCDC1, CD279 |  | non-small cell lung cancer
Tisotumab vedotin[12] | Tivdak | mab | human | coagulation factor III | Y | relapsed or refractory cervical cancer[114][115]
Tixagevimab[28] |  | mab | human | spike protein receptor binding domain (RBD) of SARS-CoV-2 | Emergency Use Authorization (EUA) when used with cilgavimab[47] | COVID-19
TNX-650 |  |  | humanized | IL-13 |  | Hodgkin's lymphoma
Tocilizumab[9] | Actemra, RoActemra | mab | humanized | IL-6 receptor | Y[116] | rheumatoid arthritis
Tomuzotuximab[27] |  | mab | humanized | Epidermal growth factor receptor (EGFR), HER1 |  | cancer
Toralizumab[21] |  | mab | humanized | CD154 (CD40L) |  | rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab[4] |  | mab | human | Staphylococcus aureus |  |
Tositumomab | Bexxar |  | mouse | CD20 | Y | follicular lymphoma
Tovetumab |  | mab | human | PDGFRA |  | cancer
Tralokinumab[117] | Adtralza, Adbry[118] | mab | human | IL-13 | Y[118] | atopic dermatitis
Trastuzumab | Herceptin | mab | humanized | HER2/neu | Y | breast cancer
Trastuzumab duocarmazine[22] | Kadcyla | mab | humanized | HER2/neu | Y | breast cancer
Trastuzumab emtansine | Kadcyla | mab | humanized | HER2/neu | Y | breast cancer
TRBS07[119] | Ektomab | 3funct |  | GD2 ganglioside |  | melanoma
Tregalizumab[16] |  | mab | humanized | CD4 |  |
Tremelimumab[120] | Imjudo | mab | human | CTLA-4 | Y[121] | hepatocellular carcinoma
Trevogrumab |  | mab | human | growth differentiation factor 8 |  | muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin[55][97] |  | mab | humanized | EpCAM |  | cancer
Tuvirumab |  |  | human | hepatitis B virus |  | chronic hepatitis B
Ublituximab[122] | Briumvi | mab | chimeric | CD20 | Y | multiple sclerosis, chronic lymphocytic leukemia
Ulocuplumab[52] |  | mab | human | CXCR4 (CD184) |  | hematologic malignancies
Urelumab[16] |  | mab | human | 4-1BB (CD137) |  | cancer etc.
Urtoxazumab[9] |  | mab | humanized | Escherichia coli |  | diarrhoea caused by E. coli
Ustekinumab[48] | Stelara | mab | human | IL-12, IL-23 | Y | multiple sclerosis, psoriasis, psoriatic arthritis
Utomilumab[22] |  | mab | human | 4-1BB (CD137) |  | diffuse large B-cell lymphoma
Vadastuximab talirine[12] |  | mab | chimeric | CD33 |  | Acute myeloid leukemia
Vanalimab[5] |  | mab | humanized | CD40 |  |
Vandortuzumab vedotin[25] |  | mab | humanized | STEAP1 |  | cancer
Vantictumab |  | mab | human | Frizzled receptor |  | cancer
Vanucizumab[6] |  | mab | humanized | angiopoietin 2 |  | cancer
Vapaliximab[21] |  | mab | chimeric | AOC3 (VAP-1) |  |
Varisacumab[27] |  | mab | human | VEGF-A |  | angiogenesis
Varlilumab[6] |  | mab | human | CD27 |  | solid tumors and hematologic malignancies
Vatelizumab[41] |  | mab | humanized | ITGA2 (CD49b) |  |
Vedolizumab[94] | Entyvio | mab | humanized | integrin α4 β7 | Y[123] | Crohn's disease, ulcerative colitis
Veltuzumab[13] |  | mab | humanized | CD20 |  | non-Hodgkin's lymphoma
Vepalimomab |  | mab | mouse | AOC3 (VAP-1) |  | inflammation
Vesencumab[16] |  | mab | human | NRP1 |  | solid malignancies
Vilobelimab[83] | Gohibic | mab | chimeric | C5a receptor (C5a) | Emergency Use Authorization (EUA)[124] | COVID-19
Visilizumab[65] | Nuvion | mab | humanized | CD3 |  | Crohn's disease, ulcerative colitis
Vobarilizumab[40] |  | scFv | humanized | IL-6 receptor |  | inflammatory autoimmune diseases
Volociximab[30] |  | mab | chimeric | integrin α5β1 |  | solid tumors
Vonlerolizumab[27] |  | mab | humanized | CD134 |  | cancer
Vopratelimab[5] |  | mab | humanized | CD278, aka ICOS |  |
Vorsetuzumab mafodotin |  | mab | humanized | CD70 |  | cancer
Votumumab | HumaSPECT | mab | human | tumor antigen CTAA16.88 |  | colorectal tumors
Vunakizumab[22] |  | mab | humanized | IL-17A |  |
Xentuzumab[40] |  | mab | humanized | IGF-1, IGF-2 |  | ?
XMAB-5574 |  |  | humanized | CD19 |  | diffuse large B-cell lymphoma
Zalutumumab[30] |  | mab | human | Epidermal growth factor receptor (EGFR) |  | squamous cell carcinoma of the head and neck
Zanolimumab[38] |  | mab | human | CD4 |  | rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab[15] |  | mab | chimeric | HER1 |  | cancer
Zenocutuzumab[26] |  | mab | humanized | ERBB3 (HER3) |  | cancer
Ziralimumab[65] |  | mab | human | CD147 (basigin) |  |
Zolbetuximab[26] |  | mab | chimeric | Claudin 18 Isoform 2 |  | gastric cancer, gastrointestinal adenocarcinoma and pancreatic cancer
Zolimomab aritox |  | mab | mouse | CD5 |  | systemic lupus erythematosus, graft-versus-host disease

## References

1. ↑ 1.0 1.1 1.2 1.3 1.4 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 57". WHO Drug Information 21 (1). 2007.
2. ↑ 2.0 2.1 2.2 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 80". WHO Drug Information 12 (4). 1998. https://www.who.int/medicines/publications/druginformation/innlists/PL80.pdf. Retrieved 23 January 2020.
3. ↑ "ReoPro Abciximab". 4 May 2020. https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=486252.
4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information 28 (1). 2014.
5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 5.14 5.15 5.16 5.17 5.18 5.19 5.20 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 118". WHO Drug Information 31 (4). 2017. https://www.who.int/medicines/publications/druginformation/innlists/PL118.pdf. Retrieved 5 October 2020.
6. ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 6.13 6.14 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 111". WHO Drug Information 28 (2). 2014. https://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf. Retrieved 5 October 2020.
7. ↑ 7.0 7.1 7.2 7.3 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 85". WHO Drug Information 15 (2). 2001. https://www.who.int/medicines/publications/druginformation/innlists/PL85.pdf. Retrieved 23 January 2020.
8. ↑ "Humira- adalimumab kit Humira- adalimumab injection, solution". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d#section-1.
9. ↑ 9.0 9.1 9.2 9.3 9.4 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 90". WHO Drug Information 18 (1). 2004. https://www.who.int/medicines/publications/druginformation/innlists/PL90.pdf. Retrieved 23 January 2020.
10. ↑ 10.0 10.1 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information 28 (3). 2014.
11. ↑ "Aduhelm- aducanumab injection, solution". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41706573-546f-6774-6872-5374726f6e67.
12. ↑ 12.00 12.01 12.02 12.03 12.04 12.05 12.06 12.07 12.08 12.09 12.10 12.11 12.12 12.13 12.14 12.15 12.16 12.17 12.18 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information 30 (1). 2016.
13. ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 98". WHO Drug Information 21 (4). 2007. https://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf. Retrieved 5 October 2020.
14. ↑ 14.0 14.1 14.2 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 83". WHO Drug Information 14 (2). 2000. https://www.who.int/medicines/publications/druginformation/innlists/PL83.pdf. Retrieved 23 January 2020.
15. ↑ 15.00 15.01 15.02 15.03 15.04 15.05 15.06 15.07 15.08 15.09 15.10 15.11 15.12 15.13 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 107". WHO Drug Information 26 (2). 2012. https://www.who.int/medicines/publications/druginformation/innlists/PL107.pdf. Retrieved 23 January 2020.
16. ↑ 16.00 16.01 16.02 16.03 16.04 16.05 16.06 16.07 16.08 16.09 16.10 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104". WHO Drug Information 24 (4). 2010. https://www.who.int/medicines/publications/druginformation/innlists/PL104.pdf. Retrieved 23 January 2020.
17. ↑ 17.0 17.1 17.2 17.3 17.4 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 86". WHO Drug Information 16 (1). 2002. https://www.who.int/medicines/publications/druginformation/innlists/PL86.pdf. Retrieved 23 January 2020.
18. ↑ 18.0 18.1 18.2 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 115". WHO Drug Information 30 (2). 2016. https://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf. Retrieved 5 October 2020.
19. ↑ "Saphnelo- anifrolumab injection, solution". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6203302-2128-41a7-b0b4-0e6c0704d4dc.
20. ↑ "Wyeth.com | Complete Project Listing". Wyeth. 2008. http://www.wyeth.com/research/projects.
21. ↑ 21.0 21.1 21.2 21.3 21.4 21.5 21.6 21.7 21.8 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 87". WHO Drug Information 16 (2). 2002. https://www.who.int/medicines/publications/druginformation/innlists/PL87.pdf. Retrieved 23 January 2020.
22. ↑ 22.00 22.01 22.02 22.03 22.04 22.05 22.06 22.07 22.08 22.09 22.10 22.11 22.12 22.13 22.14 22.15 22.16 22.17 22.18 22.19 22.20 22.21 22.22 22.23 22.24 22.25 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information 31 (1). 2017.
23. ↑ "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 74". WHO Drug Information 9 (4). 1995. https://www.who.int/medicines/publications/druginformation/innlists/PL74.pdf. Retrieved 24 January 2020.
24. ↑ 24.0 24.1 24.2 24.3 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 88". WHO Drug Information 17 (1). 2003. https://www.who.int/medicines/publications/druginformation/innlists/PL88.pdf. Retrieved 23 January 2020.
25. ↑ 25.00 25.01 25.02 25.03 25.04 25.05 25.06 25.07 25.08 25.09 25.10 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 112". WHO Drug Information 28 (4). 2014. https://www.who.int/medicines/publications/druginformation/innlists/PL112.pdf. Retrieved 5 October 2020.
26. ↑ 26.00 26.01 26.02 26.03 26.04 26.05 26.06 26.07 26.08 26.09 26.10 26.11 26.12 26.13 26.14 26.15 26.16 26.17 26.18 26.19 26.20 26.21 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 117". WHO Drug Information 31 (2). 2017. https://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf. Retrieved 5 October 2020.
27. ↑ 27.00 27.01 27.02 27.03 27.04 27.05 27.06 27.07 27.08 27.09 27.10 27.11 27.12 27.13 27.14 27.15 27.16 27.17 27.18 27.19 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 116". WHO Drug Information 30 (4). 2016. https://www.who.int/medicines/publications/druginformation/innlists/PL116.pdf. Retrieved 5 October 2020.
28. ↑ 28.0 28.1 28.2 28.3 28.4 28.5 28.6 28.7 28.8 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information 35 (1). 2021.
29. ↑ 29.0 29.1 "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab and Etesevimab" (PDF). U.S. Food and Drug Administration (FDA). https://www.fda.gov/media/145802/download.
30. ↑ 30.0 30.1 30.2 30.3 30.4 30.5 30.6 30.7 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 93". WHO Drug Information 19 (2). 2008. https://www.who.int/medicines/publications/druginformation/innlists/PL93.pdf. Retrieved 23 January 2020.
31. ↑ 31.00 31.01 31.02 31.03 31.04 31.05 31.06 31.07 31.08 31.09 31.10 31.11 31.12 31.13 31.14 31.15 31.16 31.17 International Nonproprietary Names (INN) for biological and biotechnological substances. World Health Organization (WHO). 2019. WHO/EMP/RHT/TSN/2019.1. https://www.who.int/medicines/services/inn/BioReview2019.pdf. Retrieved 22 January 2020.
32. ↑ World Health Organization (2021). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 126 – COVID-19 (special edition)". WHO Drug Information 35 (4): 1130–1. https://www.who.int/publications/i/item/who-drug-information
volume-35-no.-4. Retrieved 13 February 2022.
33. ↑ "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bebtelovimab" (PDF). U.S. Food and Drug Administration (FDA). https://www.fda.gov/media/156152/download.
34. ↑ 34.0 34.1 34.2 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information 33 (3). 2019.
35. ↑ 35.0 35.1 35.2 "Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 - via Business Wire.
36. ↑ 36.0 36.1 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 89". WHO Drug Information 17 (3). 2003. https://www.who.int/entity/medicines/publications/druginformation/innlists/PL89.pdf.
37. ↑ 37.0 37.1 37.2 37.3 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 102". WHO Drug Information 23 (4). 2009. https://www.who.int/medicines/publications/druginformation/innlists/PL102.pdf. Retrieved 23 January 2020.
38. ↑ 38.0 38.1 38.2 38.3 38.4 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 92". WHO Drug Information 18 (4). 2004. https://www.who.int/medicines/publications/druginformation/innlists/PL92.pdf. Retrieved 23 January 2020.
39. ↑ 39.0 39.1 39.2 39.3 39.4 39.5 39.6 39.7 39.8 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 108". WHO Drug Information 26 (4). 2012. https://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf. Retrieved 5 October 2020.
40. ↑ 40.00 40.01 40.02 40.03 40.04 40.05 40.06 40.07 40.08 40.09 40.10 40.11 40.12 40.13 40.14 40.15 40.16 40.17 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 114". WHO Drug Information 29 (4). 2015. https://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf. Retrieved 5 October 2020.
41. ↑ 41.00 41.01 41.02 41.03 41.04 41.05 41.06 41.07 41.08 41.09 41.10 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 105". WHO Drug Information 25 (2). 2011. https://www.who.int/medicines/publications/druginformation/innlists/PL105.pdf. Retrieved 23 January 2020.
42. ↑ 42.0 42.1 42.2 42.3 42.4 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 97". WHO Drug Information 21 (2). 2007. https://www.who.int/medicines/publications/druginformation/innlists/PL97.pdf. Retrieved 23 January 2020.
43. ↑ 43.0 43.1 43.2 43.3 43.4 43.5 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 106". WHO Drug Information 25 (4). 2011. https://www.who.int/medicines/publications/druginformation/innlists/PL106.pdf. Retrieved 23 January 2020.
44. ↑ 44.0 44.1 "Ronapreve EPAR". 10 November 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/ronapreve.
45. ↑ 45.0 45.1 "Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19". Roche (Press release). 20 July 2021. Archived from the original on 24 July 2021. Retrieved 29 August 2021.
46. ↑ 46.0 46.1 46.2 46.3 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 81". WHO Drug Information 13 (2). 1999. https://www.who.int/medicines/publications/druginformation/innlists/PL81.pdf. Retrieved 23 January 2020.
47. ↑ 47.0 47.1 "Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals". U.S. Food and Drug Administration (FDA) (Press release). 8 December 2021. Archived from the original on 28 April 2022. Retrieved 9 December 2021. This article incorporates text from this source, which is in the public domain.
48. ↑ 48.0 48.1 48.2 48.3 48.4 48.5 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 99". WHO Drug Information 22 (2). 2008. https://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf. Retrieved 5 October 2020.
49. ↑ "BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009. http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire.
50. ↑ 50.0 50.1 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information 27 (3). 2013.
51. ↑ "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 78". WHO Drug Information 11 (4). 1997. https://www.who.int/medicines/publications/druginformation/innlists/PL78.pdf. Retrieved 23 January 2020.
52. ↑ 52.0 52.1 52.2 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 110". WHO Drug Information 27 (4). 2013. https://www.who.int/medicines/publications/druginformation/innlists/PL110.pdf. Retrieved 5 October 2020.
53. ↑ 53.0 53.1 53.2 53.3 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 101". WHO Drug Information 23 (2). 2009. https://www.who.int/medicines/publications/druginformation/innlists/PL101.pdf. Retrieved 23 January 2020.
54. ↑ "Darzalex- daratumumab injection, solution, concentrate Darzalex IV- daratumumab injection, solution, concentrate". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4d0efe9-5e54-467e-9eb4-56fa7d53b60b.
55. ↑ 55.0 55.1 55.2 55.3 55.4 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 94". WHO Drug Information 19 (4). 2005. https://www.who.int/medicines/publications/druginformation/innlists/PL94.pdf. Retrieved 23 January 2020.
56. ↑ "Ivlizi (divozilimab) Concentrate for Solution for Infusion. Full Prescribing Information" (in ru). JSC Biocad. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=588dfb7f-fdc5-4d4f-a11a-92c19f3d3bcc.
57. ↑ "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 66". WHO Drug Information 5 (4). 1991. https://www.who.int/medicines/publications/druginformation/innlists/PL66.pdf. Retrieved 23 January 2020.
58. ↑ 58.0 58.1 58.2 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 119". WHO Drug Information 32 (2). 2018. https://www.who.int/medicines/publications/druginformation/innlists/PL119.pdf. Retrieved 5 October 2020.
59. ↑ "Padcev ejfv- enfortumab vedotin injection, powder, lyophilized, for solution". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed.
60. ↑ "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 77". WHO Drug Information 11 (2). 1997. https://www.who.int/medicines/publications/druginformation/innlists/PL77.pdf. Retrieved 23 January 2020.
61. ↑ 61.0 61.1 61.2 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information 34 (1). 2020.
62. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information 36 (3). 2022.
63. ↑ "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 51". WHO Drug Information 18 (1). 2004. https://www.who.int/medicines/publications/druginformation/innlists/PL51.pdf. Retrieved 23 January 2020.
64. ↑ "Vyepti- eptinezumab-jjmr injection". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=79065861-6aa5-4d1f-829f-3a6471286b36.
65. ↑ 65.0 65.1 65.2 65.3 65.4 65.5 65.6 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 84". WHO Drug Information 14 (4). 2000. https://www.who.int/medicines/publications/druginformation/innlists/PL84.pdf. Retrieved 23 January 2020.
66. ↑ 66.0 66.1 66.2 66.3 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 91". WHO Drug Information 18 (2). 2004. https://www.who.int/medicines/publications/druginformation/innlists/PL91.pdf. Retrieved 23 January 2020.
67. ↑ 67.0 67.1 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information 32 (3). 2018.
68. ↑ Buhmann, R et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.
69. ↑ Boehrer, S et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160.
70. ↑ Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
71. ↑ Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
72. ↑ 72.0 72.1 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 113". WHO Drug Information 29 (2). 2015. https://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf. Retrieved 5 October 2020.
73. ↑ 73.0 73.1 73.2 73.3 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 103". WHO Drug Information. 2011. https://www.who.int/medicines/publications/druginformation/innlists/PL103.pdf. Retrieved 23 January 2020.
74. ↑ 74.0 74.1 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information 31 (3). 2017.
75. ↑ 75.0 75.1 75.2 "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022. This article incorporates text from this source, which is in the public domain.
76. ↑ "Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®" (Press release). Archived from the original on 7 July 2017. Retrieved 2 May 2011.
77. ↑ NCI Drug Dictionary: Glemtumumab vedotin
78. ↑ 78.0 78.1 78.2 "FDA approves Roche's Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma" (Press release). F. Hoffmann-La Roche Ltd. 16 June 2023. Retrieved 16 June 2023 - via GlobeNewswire.
79. ↑ "Results from Cure Brain Cancer Foundation-funded trial show promise". http://www.curebraincancer.org.au/news/1752/results-from-cure-brain-cancer-foundation-funded-trial-show-promise.
80. ↑ "Uplizna- inebilizumab injection". 8 July 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ce5e7f6-eb97-4738-8b10-43b89e16b5b3.
81. ↑ Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
82. ↑ Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
83. ↑ 83.0 83.1 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information 34 (3). 2020.
84. ↑ "FDA Grants Accelerated Approval for Alzheimer's Disease Treatment". U.S. Food and Drug Administration (FDA) (Press release). 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023.
85. ↑ 85.0 85.1 85.2 "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information 32 (1). 2018.
86. ↑ 86.0 86.1 Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. https://www.vetnurse.co.uk/b/veterinary-nursing-news/archive/2017/06/27/zoetis-launches-breakthrough-treatment-for-canine-atopic-dermatitis.aspx.
87. ↑ "Margenza: FDA-Approved Drugs". https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150.
88. ↑ "FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer". 14 November 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant.
89. ↑ 89.0 89.1 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 79". WHO Drug Information 12 (2). 1998. https://www.who.int/medicines/publications/druginformation/innlists/PL79.pdf. Retrieved 23 January 2020.
90. ↑ "FDA grants accelerated approval to mosunetuzumab-axgb". 22 December 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma.
91. ↑ Wilde, Michelle I.; Goa, Karen L. (1 May 1996). "Muromonab CD3" (in en). Drugs 51 (5): 865–894. doi:10.2165/00003495-199651050-00010. ISSN 1179-1950. PMID 8861551.
92. ↑ Hooks, M. A.; Wade, C. S.; Millikan, W. J. (1991). "Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation". Pharmacotherapy 11 (1): 26–37. ISSN 0277-0008. PMID 1902291. https://pubmed.ncbi.nlm.nih.gov/1902291. Retrieved 10 September 2021.
93. ↑ "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 96". WHO Drug Information 20 (4). 2006. https://www.who.int/medicines/publications/druginformation/innlists/PL96.pdf. Retrieved 23 January 2020.
94. ↑ 94.0 94.1 94.2 94.3 94.4 94.5 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 100 (prepublication copy)". WHO Drug Information. 2008. https://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf. Retrieved 5 October 2020.
95. ↑ Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grazyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi et al. (2017). "Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis". New England Journal of Medicine 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150.
96. ↑ "Efleira (netakimab) Solution for Subcutaneous Use. Full Prescribing Information" (in ru). JSC Biocad. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c2bec935-e589-410a-934f-449003bbe818.
97. ↑ 97.0 97.1 97.2 97.3 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 56". WHO Drug Information 20 (3). 2006. https://www.who.int/medicines/publications/druginformation/innlists/PL56.pdf. Retrieved 23 January 2020.
98. ↑ 98.0 98.1 "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 95". WHO Drug Information 20 (2). 2006. https://www.who.int/medicines/publications/druginformation/innlists/PL95.pdf. Retrieved 23 January 2020.
99. ↑ 99.0 99.1 "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis" (Press release). Novartis. 20 August 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
100. ↑ "Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". 17 September 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287.
101. ↑ 101.0 101.1 "Regkirona EPAR". 10 November 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/regkirona.
102. ↑ "ZYNYZ™ (retifanlimab-dlwr) injection, for intravenous use". https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334s000lbl.pdf.
103. ↑ "Rituxan- rituximab injection, solution". 6 November 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563.
104. ↑ "UCB announces U.S. FDA approval of Rystiggo (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis" (Press release). UCB. 27 June 2023. Retrieved 28 June 2023 - via PR Newswire.
105. ↑ "Trodelvy- sacituzumab govitecan powder, for solution". https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d.
106. ↑ Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology 218 (1): 192–198. doi:10.1002/jcp.21588. PMID 18781584.
107. ↑ "AusPAR: Sotrovimab". 20 August 2021. https://www.tga.gov.au/auspar/auspar-sotrovimab.
108. ↑ "Xevudy EPAR". 15 December 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/xevudy.
109. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information 33 (1). 2019.
110. ↑ "Janssen Marks First Approval Worldwide for Tecvayli (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma". Janssen Pharmaceutical Companies (Press release). 24 August 2022. Archived from the original on 26 October 2022. Retrieved 26 October 2022.
111. ↑ "U.S. FDA Approves Tecvayli (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma". 25 October 2022. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma.
112. ↑ Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer Research 33 (1): 85–95. PMID 23267131.
113. ↑ "Tezspire- tezepelumab-ekko injection, solution". 17 December 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60f0aa03-ad25-4d48-80ce-7fcfa76f325f.
114. ↑ Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader: Beyond The Printed Page. https://www.lifescienceleader.com/doc/seattle-genetics-legacy-of-partnering-0001. Retrieved 22 February 2018.
115. ↑ "Enforcement Reports". https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208s000lbl.pdf.
116. ↑ "RoActemra EPAR". 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra.
117. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 64". WHO Drug Information 24 (3). 2010.
118. ↑ 118.0 118.1 "LEO Pharma announces FDA approval of Adbry tralokinumab". LEO Pharma (Press release). Archived from the original on 28 December 2021. Retrieved 28 December 2021.
119. ↑ Ruf, P et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099.
120. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 59". WHO Drug Information 22 (1). 2008.
121. ↑ "Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer". AstraZeneca (Press release). 26 October 2022. Archived from the original on 24 October 2022. Retrieved 26 October 2022.
122. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information 25 (3). 2011.
123. ↑ "Entyvio- vedolizumab injection, powder, lyophilized, for solution". 3 April 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c.
124. ↑ "FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19". 4 April 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-gohibic-vilobelimab-injection-treatment-covid-19.

* v
* t
* e

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")|

| Human ("-osu-")|

* Burosumab
* Denosumab

|

Humanized ("-sozu-")|

* Blosozumab
* Romosozumab

Musculoskeletal ("-mul-")|

| Human ("-mulu-")|

* Stamulumab†

|

Circulatory ("-c(i[r])-")|

| Human ("-ciru-")|

* Alirocumab
* Ascrinvacumab
* Enoticumab
* Evinacumab†
* Evolocumab
* Icrucumab
* Inclacumab
* Nesvacumab
* Orticumab
* Ramucirumab
* Rinucumab

|

Mouse ("-ciro-")|

* Biciromab‡
* Imciromab‡

Chimeric ("-cixi-")|

* Abciximab
* Volociximab

Humanized ("-cizu-")|

* Alacizumab pegol
* Bevacizumab/Ranibizumab
* Bococizumab
* Brolucizumab†
* Caplacizumab
* Demcizumab
* Etaracizumab
* Faricimab†
* Idarucizumab
* Ralpancizumab
* Tadocizumab
* Vanucizumab

Neurologic ("-ne(u)(r)-")|

| Human ("-neru-")|

* Aducanumab†
* Erenumab
* Fasinumab†
* Fulranumab
* Gantenerumab†
* Opicinumab

|

Humanized ("-nezu-"/"-neuzu-")|

* Bapineuzumab†
* Crenezumab†
* Eptinezumab
* Fremanezumab
* Galcanezumab
* Ozanezumab
* Ponezumab
* Refanezumab
* Solanezumab
* Tanezumab†

Angiogenesis inhibitor ("-anibi-")|

| Humanized ("-anibizu-")|

* Ranibizumab

|

Growth factor ("-gr(o)-")|

| Human ("-gru-")|

* Bimagrumab
* Trevogrumab

|

Humanized ("-grozu-")|

* Domagrozumab
* Landogrozumab

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

* v
* t
* e

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")|

| Human ("-limu-")|

* Immunosuppression: Abrilumab
* Adalimumab
* Anifrolumab†
* Atorolimumab
* Avelumab
* Belimumab
* Bleselumab
* Brodalumab
* Camidanlumab tesirine
* Carlumab
* Cemiplimab
* Dupilumab
* Eldelumab
* Emapalumab†
* Fresolimumab
* Golimumab
* Ianalumab†
* Lanadelumab
* Lenzilumab
* Lerdelimumab
* Lirilumab
* Mavrilimumab
* Metelimumab
* Morolimumab
* Namilumab
* Oleclumab
* Oxelumab§
* Pamrevlumab
* Placulumab
* Relatlimab†
* Sarilumab
* Sifalimumab
* Tabalumab
* Tezepelumab†
* Ulocuplumab
* Varlilumab

* Immune activation: Ipilimumab
* Atezolizumab
* Durvalumab
* Nivolumab
* Pembrolizumab
* Tremelimumab†
* Urelumab

* Other: Bertilimumab
* Zanolimumab

|

Mouse ("-limo-")|

* Afelimomab
* Elsilimomab
* Faralimomab
* Gavilimomab
* Inolimomab
* Maslimomab
* Nerelimomab
* Odulimomab
* Telimomab aritox
* Vepalimomab
* Zolimomab aritox

Chimeric ("-lixi-")|

* Andecaliximab†
* Basiliximab
* Clenoliximab
* Galiximab
* Gomiliximab
* Infliximab
* Keliximab
* Lumiliximab
* Priliximab
* Teneliximab
* Vapaliximab

Humanized ("-lizu-")|

* Immunosuppressive: Aselizumab
* Apolizumab§
* Benralizumab
* Camrelizumab†
* Cedelizumab
* Certolizumab pegol
* Crizanlizumab†
* Daclizumab
* Dostarlimab†
* Eculizumab
* Efalizumab
* Epratuzumab
* Erlizumab
* Etrolizumab†
* Fontolizumab
* Inebilizumab†
* Itolizumab
* Lampalizumab†
* Letolizumab
* Ligelizumab†
* Lulizumab pegol
* Mepolizumab
* Mogamulizumab
* Natalizumab
* Ocrelizumab
* Omalizumab
* Ozoralizumab
* Pascolizumab
* Pateclizumab
* Pembrolizumab
* Pexelizumab
* Pidilizumab
* Plozalizumab
* PRO 140†
* Quilizumab
* Ravulizumab
* Reslizumab
* Rontalizumab
* Rovelizumab
* Ruplizumab
* Samalizumab
* Satralizumab†
* Siplizumab
* Spartalizumab†
* Talizumab
* Teplizumab
* Tislelizumab
* Tocilizumab
* Toralizumab
* Tregalizumab
* Vatelizumab
* Vedolizumab
* Visilizumab
* Vobarilizumab
* TGN1412§
Non-immunosuppressive: Ibalizumab

Chimeric + humanized
("-lixizu-")|

* Otelixizumab
* Sutimlimab†

Interleukin ("-k(i[n])-")|

| Human ("-kinu-")|

* Bermekimab
* Brazikumab
* Briakinumab
* Canakinumab
* Fezakinumab
* Fletikumab
* Guselkumab
* Secukinumab
* Sirukumab
* Tralokinumab†
* Ustekinumab

|

Humanized ("-kizu-", "-kinzu-")|

* Anrukinzumab
* Bimekizumab†
* Clazakizumab
* Gevokizumab
* Ixekizumab
* Mirikizumab†
* Lebrikizumab
* Olokizumab†
* Perakizumab
* Risankizumab
* Tildrakizumab

Veterinary ("-kivet-")|

* Lokivetmab

Inflammatory lesions ("-les-")|

| Mouse ("-leso-")|

* Besilesomab
* Fanolesomab‡
* Lemalesomab
* Sulesomab

|

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

* v
* t
* e

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")|

| Human ("-fungu-")|

* Efungumab†

|

Viral ("-v(i)[r]-")|

| Human ("-viru-")|

* Diridavumab§
* Exbivirumab§
* Foravirumab§
* Libivirumab§
* Rafivirumab§
* Regavirumab§
* Sevirumab†
* Suptavumab
* Tuvirumab§

|

Chimeric ("-vixi-")|

* Cosfroviximab
* Larcaviximab
* Porgaviximab

Humanized ("-vizu-")|

* Felvizumab§
* Lenvervimab†
* Motavizumab†
* Palivizumab
* Suvizumab§

Bacterial ("-ba(c)-")|

| Human ("-bacu-")|

* Nebacumab
* Panobacumab§
* Raxibacumab

|

Mouse ("-baco-")|

* Edobacomab§

Chimeric ("-baxi-")|

* Pagibaximab†

Humanized ("-bazu-")|

* Tefibazumab†

Toxin ("-tox(a)-")|

| Human ("-toxu-")|

* Actoxumab§
* Bezlotoxumab
* Suvratoxumab

|

Chimeric ("-toxaxi-")|

* Obiltoxaximab

Humanized ("-toxazu-")|

* Urtoxazumab§

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

* v
* t
* e

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")|

| Human ("-tumu-")|

* Adecatumumab§
* Ascrinvacumab§
* Cixutumumab§
* Conatumumab§
* Daratumumab
* Drozitumab§
* Duligotumab§
* Dusigitumab§
* Enfortumab vedotin†
* Enoticumab§
* Figitumumab§
* Ganitumab†
* Glembatumumab vedotin†
* Intetumumab§
* Ipilimumab
* Iratumumab§
* Istiratumab
* Icrucumab§
* Lexatumumab§
* Lucatumumab§
* Mapatumumab§
* Narnatumab§
* Necitumumab
* Nesvacumab§
* Nivolumab
* Ofatumumab
* Olaratumab†
* Panitumumab
* Patritumab§
* Pembrolizumab
* Pritumumab§
* Radretumab§
* Ramucirumab
* Rilotumumab†
* Robatumumab§
* Seribantumab§
* Tarextumab§
* Teprotumumab†
* Tovetumab§
* Vantictumab§
* Votumumab§
* Zalutumumab†

"-melu-" (melanoma)
Flanvotumab§

|

Mouse ("-tumo-")|

* Altumomab pentetate
* Anatumomab mafenatox
* Arcitumomab
* Bectumomab
* Blinatumomab
* Detumomab
* Ibritumomab tiuxetan
* Lilotomab
* Minretumomab
* Mitumomab
* Moxetumomab pasudotox†
* Naptumomab estafenatox
* Nofetumomab merpentan
* Pemtumomab†
* Pintumomab
* Racotumomab
* Satumomab pendetide
* Solitomab
* Taplitumomab paptox
* Tenatumomab
* Tositumomab
* 3F8

"-govo-" (ovarian tumor)
Abagovomab
Igovomab
Oregovomab

"-pro-" (prostate tumor)
Capromab pendetide

"-colo-" (colonic tumor)
Edrecolomab
Nacolomab tafenatox

Chimeric ("-tuxi-")|

* Amatuximab§
* Bavituximab§
* Brentuximab vedotin
* Carotuximab†
* Cetuximab
* Derlotuximab biotin§
* Dinutuximab
* Ensituximab§
* Futuximab§
* Girentuximab†
* Indatuximab ravtansine§
* Isatuximab†
* Loncastuximab tesirine
* Margetuximab†
* Rituximab#
* Siltuximab
* Ublituximab†
* IMAB362

"-mexi-" (melanoma): Ecromeximab§

Humanized ("-tuzu-")|

* Abituzumab§
* Alemtuzumab
* Bevacizumab
* Bivatuzumab mertansine§
* Brontictuzumab§
* Cantuzumab mertansine§
* Cantuzumab ravtansine§
* Cirmtuzumab
* Citatuzumab bogatox§
* Clivatuzumab tetraxetan
* Cofetuzumab pelidotin
* Dacetuzumab§
* Demcizumab§
* Dalotuzumab§
* Denintuzumab mafodotin§
* Elotuzumab
* Emactuzumab§
* Emibetuzumab§
* Enoblituzumab§
* Etaracizumab§
* Farletuzumab§
* Ficlatuzumab§
* Flotetuzumab§
* Gemtuzumab ozogamicin‡
* Imgatuzumab§
* Inotuzumab ozogamicin†
* Labetuzumab§
* Lifastuzumab vedotin§
* Lintuzumab§
* Lorvotuzumab mertansine§
* Lumretuzumab§
* Matuzumab§
* Milatuzumab§
* Nimotuzumab†
* Obinutuzumab
* Ocaratuzumab§
* Otlertuzumab§
* Onartuzumab§
* Oportuzumab monatox†
* Parsatuzumab§
* Pertuzumab
* Pinatuzumab vedotin§
* Polatuzumab vedotin†
* Rosmantuzumab
* Rovalpituzumab tesirine†
* Sacituzumab govitecan†
* Sibrotuzumab§
* Simtuzumab§
* Tacatuzumab tetraxetan§
* Tigatuzumab§
* Trastuzumab
* Tucotuzumab celmoleukin§
* Vandortuzumab vedotin§
* Vanucizumab§
* Veltuzumab§
* Vorsetuzumab mafodotin§
* CBR96-doxorubicin immunoconjugate
* PankoMab

"-gozu-" (ovarian tumor)
Sofituzumab vedotin§

Rat/mouse hybrid
("-tumaxo-")|

* Catumaxomab
* Ertumaxomab§

Chimeric + humanized
("-tuxizu-")|

* Depatuxizumab mafodotin†
* Duvortuxizumab
* Ontuxizumab§

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/List of therapeutic monoclonal antibodies. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:List_of_therapeutic_monoclonal_antibodies&oldid=501679"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template